[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
November 4, 1933


Author Affiliations

From the John McCormick Institute for Infectious Diseases.

JAMA. 1933;101(19):1444-1447. doi:10.1001/jama.1933.02740440004002

The most important factors in the management of scarlet fever are the early diagnosis of the disease and the administration of an adequate amount of scarlet fever antitoxin. If this is done, a favorable effect will be noted on the severity of the febrile stage of the disease, on the course and duration of the fever, on the intensity and duration of the skin lesions, and on the occurrence of complications. These statements are supported by numerous reports that have appeared in the literature during the last few years, and by a study of 2,303 cases of scarlet fever admitted to the Durand Hospital during the years 1924 to 1931 inclusive, in 882 of which scarlet fever antitoxin was administered. This study deals with the last group. The antitoxin used was commercial concentrated and refined serum, standardized by means of skin tests in susceptible persons. One therapeutic dose (sufficient antitoxin

First Page Preview View Large
First page PDF preview
First page PDF preview